Monte Rosa Therapeutics, Inc.GLUENASDAQ

Revenue (LTM)

$124M

+63.5% YoY

Net Income (LTM)

$-39M

+46.9% YoY

Free Cash Flow

$-27M

Revenue CAGR (5Y)

—

Marginsimproving

FCFTurned negative

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	0	0	0	76	124↑63.5%
Gross Profit	0	0	-6	68↑1184.9%	115↑70.8%
Operating Income	-73	-112↓54.2%	-143↓27.5%	-81↑43.4%	-54↑33.2%
Net Income	-74	-109↓46.7%	-135↓24.7%	-73↑46.3%	-39↑46.9%
EBITDA	-71	-109↓53.6%	-137↓26.2%	-73↑46.8%	-46↑37.2%
EPS Diluted	-1.59	-2.30↓44.7%	-2.63↓14.3%	-0.98↑62.7%	-0.46↑53.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	346	55↓84.1%	128↑133.3%	224↑75.1%	130↓42.1%
Total Current Assets	349	276↓20.9%	236↓14.4%	377↑59.8%	393↑4.2%
Total Assets	366	342↓6.5%	304↓11.3%	439↑44.4%	449↑2.3%
Total Current Liabilities	17	26↑53.7%	47↑82.2%	157↑236.9%	64↓59.1%
Total Liabilities	19	71↑277.3%	125↑75.4%	216↑73.3%	216↓0.1%
Total Equity	348	271↓21.9%	179↓34.0%	223↑24.4%	233↑4.5%
Total Debt	0	47	46↓2.0%	43↓7.2%	39↓8.3%
Net Debt	-346	-8↑97.7%	-82↓937.3%	-182↓121.2%	-91↑50.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-59	-92↓55.8%	-44↑52.6%	42↑195.9%	-23↓154.3%
Capital Expenditure	-10	-13↓32.7%	-19↓47.5%	-4↑79.1%	-5↓17.9%
Free Cash Flow	-69	-105↓52.5%	-63↑40.4%	38↑160.5%	-27↓172.3%
Stock-Based Comp	5	12↑124.3%	17↑42.9%	18↑8.7%	19↑4.1%
Net Change in Cash	309	-291↓194.4%	72↑124.9%	96↑33.0%	-94↓197.8%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance